-DOCSTART- -X- O
Glycoconjugate -X- _ O
vaccines -X- _ O
based -X- _ O
on -X- _ O
bacterial -X- _ O
capsular -X- _ O
polysaccharides -X- _ O
( -X- _ O
CPS -X- _ O
) -X- _ O
have -X- _ O
been -X- _ O
extremely -X- _ O
successful -X- _ O
in -X- _ O
preventing -X- _ O
bacterial -X- _ O
infections. -X- _ O
The -X- _ O
glycan -X- _ O
antigens -X- _ O
for -X- _ O
the -X- _ O
preparation -X- _ O
of -X- _ O
CPS -X- _ O
based -X- _ O
glycoconjugate -X- _ O
vaccines -X- _ O
are -X- _ O
mainly -X- _ O
obtained -X- _ O
from -X- _ O
bacterial -X- _ O
fermentation -X- _ O
, -X- _ O
the -X- _ O
quality -X- _ O
and -X- _ O
length -X- _ O
of -X- _ O
glycans -X- _ O
are -X- _ O
always -X- _ O
inconsistent. -X- _ O
Such -X- _ O
kind -X- _ O
of -X- _ O
situation -X- _ O
make -X- _ O
the -X- _ O
CMC -X- _ O
of -X- _ O
glycoconjugate -X- _ O
vaccines -X- _ O
are -X- _ O
difficult -X- _ O
to -X- _ O
well -X- _ O
control. -X- _ O
Thanks -X- _ O
to -X- _ O
the -X- _ O
advantage -X- _ O
of -X- _ O
synthetic -X- _ O
methods -X- _ O
for -X- _ O
carbohydrates -X- _ O
syntheses. -X- _ O
The -X- _ O
well -X- _ O
controlled -X- _ O
glycan -X- _ O
antigens -X- _ O
are -X- _ O
more -X- _ O
easily -X- _ O
to -X- _ O
obtain -X- _ O
, -X- _ O
and -X- _ O
them -X- _ O
are -X- _ O
conjugated -X- _ O
to -X- _ O
carrier -X- _ O
protein -X- _ O
to -X- _ O
from -X- _ O
the -X- _ O
so-call -X- _ O
homogeneous -X- _ O
fully -X- _ B-Intervention
synthetic -X- _ I-Intervention
glycoconjugate -X- _ I-Intervention
vaccines. -X- _ I-Intervention
Several -X- _ O
fully -X- _ O
glycoconjugate -X- _ O
vaccines -X- _ O
are -X- _ O
in -X- _ O
different -X- _ O
phases -X- _ O
of -X- _ O
clinical -X- _ O
trial -X- _ O
for -X- _ O
bacteria -X- _ B-Patient
or -X- _ I-Patient
cancers. -X- _ I-Patient
The -X- _ O
review -X- _ O
will -X- _ O
introduce -X- _ O
the -X- _ O
recent -X- _ O
development -X- _ O
of -X- _ O
fully -X- _ O
synthetic -X- _ O
glycoconjugate -X- _ O
vaccine -X- _ O
. -X- _ O

